Pages that link to "Q36775219"
Jump to navigation
Jump to search
The following pages link to A randomized exploratory trial of an α-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia (Q36775219):
Displaying 50 items.
- Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options (Q22241447) (← links)
- Modulatory effects of α7 nAChRs on the immune system and its relevance for CNS disorders (Q26765419) (← links)
- Brain Functional Effects of Psychopharmacological Treatments in Schizophrenia: A Network-based Functional Perspective Beyond Neurotransmitter Systems (Q26786247) (← links)
- Translational Rodent Paradigms to Investigate Neuromechanisms Underlying Behaviors Relevant to Amotivation and Altered Reward Processing in Schizophrenia (Q26801568) (← links)
- A mouse model of the 15q13.3 microdeletion syndrome shows prefrontal neurophysiological dysfunctions and attentional impairment (Q27324628) (← links)
- Drug models of schizophrenia (Q28084198) (← links)
- nAChR dysfunction as a common substrate for schizophrenia and comorbid nicotine addiction: Current trends and perspectives. (Q30362464) (← links)
- Nicotinic ligands as multifunctional agents for the treatment of neuropsychiatric disorders (Q30372351) (← links)
- Maximizing the effect of an α7 nicotinic receptor PAM in a mouse model of schizophrenia-like sensory inhibition deficits. (Q30381001) (← links)
- Effects of the nicotinic α7 receptor partial agonist GTS-21 on NMDA-glutamatergic receptor related deficits in sensorimotor gating and recognition memory in rats (Q30391389) (← links)
- Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia (Q30428422) (← links)
- Design, synthesis, and activity of a series of arylpyrid-3-ylmethanones as type I positive allosteric modulators of α7 nicotinic acetylcholine receptors (Q30570721) (← links)
- Neurology issues in schizophrenia. (Q30910367) (← links)
- Neurobiological background of negative symptoms (Q30913824) (← links)
- In vivo evidence for β2 nicotinic acetylcholine receptor subunit upregulation in smokers as compared with nonsmokers with schizophrenia (Q33605318) (← links)
- A randomized, placebo-controlled study investigating the nicotinic α7 agonist, RG3487, for cognitive deficits in schizophrenia (Q33620592) (← links)
- The α7 nicotinic receptor agonist ABT-107 decreases L-Dopa-induced dyskinesias in parkinsonian monkeys (Q34186299) (← links)
- Lynx1 shifts α4β2 nicotinic receptor subunit stoichiometry by affecting assembly in the endoplasmic reticulum. (Q34467639) (← links)
- The α7 Nicotinic Agonist ABT-126 in the Treatment of Cognitive Impairment Associated with Schizophrenia in Nonsmokers: Results from a Randomized Controlled Phase 2b Study (Q34531316) (← links)
- Optimizing treatments for nicotine dependence by increasing cognitive performance during withdrawal. (Q34870758) (← links)
- Selective serotonin 3 receptor antagonist treatment for schizophrenia: meta-analysis and systematic review. (Q34879435) (← links)
- Investigation of cigarette smoking among male schizophrenia patients (Q34970938) (← links)
- Reliability and validity of the CogState battery Chinese language version in schizophrenia. (Q34984648) (← links)
- AQW051, a novel, potent and selective α7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation (Q35111465) (← links)
- Varenicline for smoking cessation in people with schizophrenia: systematic review and meta-analysis. (Q35302795) (← links)
- The 4th Schizophrenia International Research Society Conference, 5-9 April 2014, Florence, Italy: a summary of topics and trends (Q35382798) (← links)
- Do negative symptoms of schizophrenia change over time? A meta-analysis of longitudinal data (Q35450483) (← links)
- An Open Study of Sulforaphane-rich Broccoli Sprout Extract in Patients with Schizophrenia. (Q35579197) (← links)
- Design and Synthesis of Nicotinic Acetylcholine Receptor Antagonists and their Effect on Cognitive Impairment. (Q35733853) (← links)
- Discovery, synthesis, biological evaluation and structure-based optimization of novel piperidine derivatives as acetylcholine-binding protein ligands (Q36213170) (← links)
- Alpha-7 nicotinic agonists for cognitive deficits in neuropsychiatric disorders: A translational meta-analysis of rodent and human studies (Q36243977) (← links)
- Identification and in vitro pharmacological characterization of a novel and selective α7 nicotinic acetylcholine receptor agonist, Br-IQ17B. (Q36287717) (← links)
- α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage (Q36469995) (← links)
- Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia (Q36579938) (← links)
- Cholinergic connectivity: it's implications for psychiatric disorders. (Q36812599) (← links)
- Nicotinic receptors in neurodegeneration (Q36828916) (← links)
- Reward learning as a potential target for pharmacological augmentation of cognitive remediation for schizophrenia: a roadmap for preclinical development (Q36935148) (← links)
- Targeting alpha-7 nicotinic neurotransmission in schizophrenia: a novel agonist strategy (Q37067455) (← links)
- The potential role of dopamine D₃ receptor neurotransmission in cognition. (Q37106827) (← links)
- Targeting of α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia and the Use of Auditory Sensory Gating as a Translational Biomarker (Q37258840) (← links)
- The Protective Effect of Alpha 7 Nicotinic Acetylcholine Receptor Activation on Critical Illness and Its Mechanism (Q37604595) (← links)
- Nicotinic modulation of intrinsic brain networks in schizophrenia (Q38116676) (← links)
- Neurocognitive endophenotypes in schizophrenia: modulation by nicotinic receptor systems (Q38122913) (← links)
- Pharmacotherapy of cognitive deficits in schizophrenia (Q38162531) (← links)
- Going up in smoke? A review of nAChRs-based treatment strategies for improving cognition in schizophrenia (Q38171876) (← links)
- Nicotinic receptors and attention (Q38345699) (← links)
- Drug repurposing and emerging adjunctive treatments for schizophrenia (Q38417631) (← links)
- The therapeutic potential of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia (Q38560778) (← links)
- Pharmacokinetic Limitations on Effects of an Alpha7 Nicotinic Receptor Agonist in Schizophrenia: Randomized Trial with an Extended Release Formulation (Q38639637) (← links)
- Therapeutic Implications of Brain-Immune Interactions: Treatment in Translation (Q38828405) (← links)